Leading BioSciences

Leading BioSciences, Inc. (LBS) is a biopharmaceutical company that has developed a revolutionary medical platform based on autodigestive science. The company's lead candidate product (LB1148) is intended for the treatment of severe sepsis, septic shock, and multi-organ failure. Additionally, the company is developing a respiratory and blood diagnostic device for the early detection of acute shock and multi-organ failure. This therapy is part of an overall product design that includes the drug formulation (LB1148) and delivery device. To date, this new medical platform has produced 14 different products, therapies, and medical devices, each with its own unique patents and exclusive licenses.